Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by serendipidyon Jan 15, 2019 6:39pm

85 Views

Post# 29236743

RE:I calling BS!!!!

again if you dont believe in this company, sell, take your lossess. Of course Salzman is still getting paid, their still doing case studies- seems reasonable to me, i like to get paid for the work i do. This is not going to happen overnite, there are hoops to go through but they are methodical in their planning. As I've said, my number is 2.00/ share, and i believe we will get there- eventually...

Bullboard Posts

Visionstate set to leverage success in the U.S. market